2016年预防性人乳头瘤病毒(HPV)疫苗接种进展:文献综述
本文综述了2016年预防性HPV疫苗接种的进展。临床试验显示疫苗在基线HPV DNA阴性的成年女性中高效,并可能预防癌前病变治疗后的HPV相关疾病;免疫原性研究支持15岁以下人群接种两剂次方案;真实世界数据显示疫苗接种地区疫苗相关HPV型别、生殖器疣和癌前病变的患病/发病率下降,且在未接种女性和男性中也有下降,提示群体保护;尽管存在争议性综合征的报道,但多项安全性研究未证实其与HPV疫苗的关联。主要挑战是在国家免疫规划中实施HPV疫苗接种,尤其是在宫颈癌负担最高的中低收入国家,并实现和维持高接种覆盖率。
要点
- 2016年临床试验显示HPV疫苗在基线HPV DNA阴性的成年女性中高效。
- 免疫原性研究支持所有三种获批疫苗在15岁以下人群使用两剂次方案。
- 真实世界数据表明疫苗接种地区HPV相关型别、生殖器疣和癌前病变下降,并提示群体保护。
核心结论
- 预防性HPV疫苗是预防HPV相关癌症尤其是宫颈癌的革命性进步,结合适当筛查有望大幅降低甚至消除宫颈癌 incidence。
研究设计与样本
- 本文为文献综述,检索并汇总2016年发表的预防性HPV疫苗相关临床研究、免疫原性研究和真实世界效果数据。
主要发现
- 2016年进一步临床试验显示疫苗在成年女性中高效,尤其是基线HPV DNA阴性者,并提示可能预防癌前宫颈病变治疗后的HPV相关疾病。
- 免疫原性研究显示所有三种获批疫苗在15岁以下人群两剂次方案的免疫应答非劣于且临床疗效相似于三剂次方案。
- 真实世界有效性数据显示在有HPV疫苗接种覆盖的国家和地区,疫苗相关HPV型别、生殖器疣和癌前宫颈病变的患病/发病率呈横断面下降,且在未接种女性和男性中也有下降,强烈提示群体保护。
- 迄今HPV型别间的自然竞争尚未被证实,因此疫苗诱导的具有临床意义的型别替换不太可能。
- 尽管临床试验和真实世界均显示良好安全性,但新出现的争议性综合征据称与HPV疫苗相关,暂时损害了一些先前非常成功的接种规划,并显著导致宫颈癌患病率最高的一些国家HPV疫苗实施失败;然而多项安全性研究在不同环境和地理位置未能证实这些综合征与HPV疫苗接种的关联。
关键数值与推荐
- 支持15岁以下个体两剂次方案的建议基于免疫原性研究显示非劣免疫应答和与三剂次方案相似的临床疗效,适用于所有三种获批疫苗。
临床怎么用
- 主要挑战仍是在国家免疫规划中实施HPV疫苗接种,尤其是在宫颈癌负担最高的中低收入国家,并实现和维持高疫苗覆盖率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate screening, it has the potential to dramatically reduce cervical cancer incidence and even eradicate it. Following extensive evaluations in clinical trials, the first decade of routine HPV vaccine use provides overwhelming evidence of the vaccines' safety and their real-life effectiveness. In 2016, further clinical trials showed high vaccine efficacy in adult women, especially those that were HPV DNA-negative at baseline, and indicated possible protection from HPV-related diseases after treatment of precancerous cervical lesions. The recommendation for a two-dose schedule in individuals under 15 is further supported for all three licensed vaccines by immunogenicity studies that show non-inferior immune responses and similar clinical efficacy compared to the three-dose schedule. So far, natural competition between HPV types has not been confirmed and therefore vaccine-induced clinically significant type replacement is unlikely. The real-world effectiveness data showed cross-sectional reduction in the prevalence/incidence of vaccine-related HPV types, genital warts and precancerous cervical lesions in countries and regions with HPV vaccination coverage. These declines were evident not only in vaccinated females, but also in unvaccinated females and males, strongly suggesting herd protection. Despite an excellent safety profile consistently demonstrated in clinical trials and confirmed in real-life settings, recently invented controversial syndromes allegedly linked to HPV vaccines temporarily compromised some previously very successful vaccination programs and significantly contributed to the failure of HPV vaccine implementation in some countries with the highest prevalence of cervical cancer. However, several safety studies failed to confirm any association of these syndromes with HPV vaccination in various settings and geographic locations. The main challenges remain implementing HPV vaccination in national vaccination programs, especially in low-and middle-income countries with the highest burden of cervical cancer, and achieving and sustaining high vaccine coverage rates.
引用
- Maver PJ, Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2017. PMID: 28801154. doi:10.1016/j.vaccine.2017.07.113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。